Salient Capital Advisors’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
Other funds holding LLY
Salient Capital Advisors's LLY Position: Q3 2017 in Review
Salient Capital Advisors sold out of Eli Lilly (LLY) in Q3 2017, closing a stake of 28,605 shares — an estimated $2.35M sold.
Salient Capital Advisors first reported a position in LLY in Q4 2013 and held it in 15 quarters. The position peaked at $13.7M in Q2 2016. 1,229 funds tracked by Wall St. Rank hold LLY as of Q3 2017.
- Salient Capital Advisors reported no remaining Eli Lilly position as of Q3 2017 after selling out during the quarter.
- Salient Capital Advisors sold 28,605 Eli Lilly shares in Q3 2017, an estimated $2.35M.
- Salient Capital Advisors first reported a position in Eli Lilly in Q4 2013 and held it in 15 quarters.
- Salient Capital Advisors's Eli Lilly position peaked at $13.7M in Q2 2016.
- 1,229 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2017.
Based on Salient Capital Advisors's 13F filing for Q3 2017, filed 6 Nov 2017.